Collection of Blood From Patients With Cancer
Recruiting
1,750 enrolled
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Phase 2 Recruiting
112 enrolled
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Phase 3 Recruiting
750 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
A Study of PHN-012 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
165 enrolled
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 Recruiting
364 enrolled
Evaluation for NCI Surgery Branch Clinical Research Protocols
Recruiting
7,000 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 4 FDA
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Phase 1 Recruiting
55 enrolled
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 Recruiting
188 enrolled
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Recruiting
200 enrolled
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Recruiting
80 enrolled
ASAP
Recruiting
25,000 enrolled
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Phase 1 Recruiting
124 enrolled
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Phase 1 Recruiting
70 enrolled
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
LUCID
Recruiting
100 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3 Recruiting
430 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
MOMENTUM
Recruiting
8,000 enrolled
CureLung
Recruiting
500 enrolled
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 Recruiting
140 enrolled
EVLC
Phase NA Recruiting
194 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
EGRET
Phase 1 Recruiting
403 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
The Florida ASCENT Study
Phase NA Recruiting
100 enrolled
VALOR
Phase NA Recruiting
670 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
BASECAMP-1
Recruiting
200 enrolled
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Phase NA Recruiting
9 enrolled
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Phase 1/2 Recruiting
534 enrolled
GEMINI-NSCLC: NSCLC Biomarker Study
Recruiting
1,200 enrolled
PERFECT-MPE
Phase NA Recruiting
98 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
EMITT-1
Phase 1/2 Recruiting
300 enrolled
EXoPERT EMERALD Clinical Study
Recruiting
1,400 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
CCANED-CIPHER
Recruiting
6,000 enrolled